Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Clinical-trials-phase-iii symbols : Abbv save search
Phase 3 SELECT-GCA Study of Upadacitinib (RINVOQ®) Showed Positive Results in Patients With Giant Cell Arteritis
Published: 2024-04-18 (Crawled : 19:00) - biospace.com/
ABBV | News | $166.43 1.08% 2M
|
Health Technology
|
| O: 0.75%
H: 0.0%
C: 0.0%
rinvoq positive cell results study
AbbVie Announces Upadacitinib (RINVOQ®) Met the Primary Endpoint in Phase 2 Clinical Trial of Vitiligo as Program Advances to Phase 3
Published: 2023-10-12 (Crawled : 11:00) - biospace.com/
ABBV | News | $166.43 1.08% 2M
|
Health Technology
|
| O: -0.65%
H: 0.0%
C: 0.0%
rinvoq abbvie program trial
AbbVie Presents Long-Term Data Further Supporting the Efficacy and Safety Profile of RINVOQ (upadacitinib) in Adults and Adolescents with Moderate to Severe Atopic Dermatitis
Published: 2023-10-11 (Crawled : 13:00) - biospace.com/
ABBV | News | $166.43 1.08% 2M
|
Health Technology
|
| O: -0.08%
H: 0.0%
C: 0.0%
abbvie dermatitis rinvoq
Journal of Cosmetic Dermatology Publishes Data Demonstrating Patient Satisfaction with Natural-Looking Outcomes Following Treatment with OnabotulinumtoxinA (BOTOX® Cosmetic)
Published: 2023-08-30 (Crawled : 15:00) - biospace.com/
ABBV | News | $166.43 1.08% 2M
|
Health Technology
|
| O: 0.41%
H: 0.0%
C: 0.0%
botox treatment
New England Journal of Medicine Publishes Results from Phase 3 Induction and Maintenance Programs Evaluating Upadacitinib (RINVOQ®) in Crohn's Disease
Published: 2023-05-25 (Crawled : 17:00) - biospace.com/
ABBV | News | $166.43 1.08% 2M
|
Health Technology
|
| O: -0.79%
H: 0.12%
C: -1.01%
rinvoq disease results
AbbVie Clinches Back-to-Back Clinical Wins in Ulcerative Colitis, Lupus
Published: 2023-03-24 (Crawled : 13:00) - biospace.com/
ABBV | News | $166.43 1.08% 2M
|
Health Technology
|
| O: -0.01%
H: 2.06%
C: 1.76%
abbvie lupus ulcerative colitis
Risankizumab (SKYRIZI®) Achieves Primary and All Secondary Endpoints in Phase 3 Induction Study in Patients With Ulcerative Colitis
Published: 2023-03-23 (Crawled : 15:00) - biospace.com/
ABBV | News | $166.43 1.08% 2M
|
Health Technology
|
| O: 0.28%
H: 1.56%
C: 0.78%
skyrizi risankizumab study ulcerative colitis
AbbVie Seeks New Indication for Migraine Drug Qulipta, Drops Deal with Morphic
Published: 2022-06-22 (Crawled : 16:00) - biospace.com/
ABBV | News | $166.43 1.08% 2M
|
Health Technology
|
| O: 2.73%
H: 4.44%
C: 2.67%
drug deal migraine
AbbVie Presents Positive Data from Phase 3 Study of Cariprazine (VRAYLAR®) for the Adjunctive Treatment of Major Depressive Disorder at 2022 APA Annual Meeting
Published: 2022-05-23 (Crawled : 16:00) - biospace.com/
ABBV | News | $166.43 1.08% 2M
|
Health Technology
|
| O: -0.51%
H: 0.0%
C: 0.0%
vraylar treatment positive phase 3 major depressive disorder
Upadacitinib (RINVOQ®) Achieved Clinical Remission and Endoscopic Response at One Year in Phase 3 Maintenance Study in Patients with Crohn's Disease
Published: 2022-05-11 (Crawled : 13:00) - biospace.com/
ABBV | News | $166.43 1.08% 2M
|
Health Technology
|
| O: 0.21%
H: 0.0%
C: 0.0%
rinvoq disease response one phase 3
AbbVie Prepares to Seek Supplemental Approval for Migraine Treatment
Published: 2022-03-10 (Crawled : 19:00) - biospace.com/
ABBV | News | $166.43 1.08% 2M
|
Health Technology
|
| O: -0.11%
H: 0.0%
C: 0.0%
treatment approval migraine
AbbVie’s SKYRIZI Offers New Option for Psoriatic Arthritis Sufferers
Published: 2022-01-24 (Crawled : 13:00) - biospace.com/
ABBV | News | $166.43 1.08% 2M
|
Health Technology
|
| O: -0.33%
H: 0.32%
C: -0.5%
skyrizi
Notch Another Win for AbbVie's Rinvoq, This Time in Psoriatic Arthritis
Published: 2021-12-15 (Crawled : 18:00) - biospace.com/
ABBV | News | $166.43 1.08% 2M
|
Health Technology
|
| O: 1.81%
H: 0.0%
C: 0.0%
rinvoq
Junshi Biosciences and Coherus Announce Positive Interim Overall Survival Results of CHOICE-01
Published: 2021-12-13 (Crawled : 18:00) - biospace.com/
ABBV | News | $166.43 1.08% 2M
|
Health Technology
|
| O: 1.07%
H: 0.0%
C: 0.0%
CHRS | $1.995 -0.25% 2M
|
Health Technology
|
| O: -0.83%
H: 0.0%
C: 0.0%
hoice-01 positive bioscience results
Upadacitinib (RINVOQ®) Achieved Primary and Key Secondary Endpoints in First Phase 3 Induction Study in Patients with Crohn's Disease
Published: 2021-12-06 (Crawled : 15:30) - biospace.com/
ABBV | News | $166.43 1.08% 2M
|
Health Technology
|
| O: 1.57%
H: 0.0%
C: 0.0%
disease phase 3
AbbVie to Present New Long-term Analysis Evaluating the Sustainability of Response to RINVOQ® (Upadacitinib) Among Patients with Rheumatoid Arthritis
Published: 2021-11-09 (Crawled : 14:15) - biospace.com/
ABBV | News | $166.43 1.08% 2M
|
Health Technology
|
| O: -0.84%
H: 0.0%
C: 0.0%
rheumatoid arthritis response
AbbVie Presents Integrated Efficacy and Safety Data From Two Phase 3 Trials on Risankizumab (SKYRIZI®) in Psoriatic Arthritis at ACR Convergence 2021
Published: 2021-11-05 (Crawled : 16:00) - biospace.com/
ABBV | News | $166.43 1.08% 2M
|
Health Technology
|
| O: -0.28%
H: 0.51%
C: 0.39%
trials phase 3 risankizumab trial
AbbVie's Cariprazine (VRAYLAR®) Met Primary Endpoint in Phase 3 Study as an Adjunctive Treatment for Major Depressive Disorder
Published: 2021-10-29 (Crawled : 12:15) - biospace.com/
ABBV | News | $166.43 1.08% 2M
|
Health Technology
|
| O: 2.31%
H: 0.0%
C: 0.0%
treatment phase 3 depression major depressive disorder
AbbVie Presents Late-Breaking Data on Risankizumab (SKYRIZI®) in Psoriatic Arthritis at the 30th European Academy of Dermatology and Venereology (EADV) Congress
Published: 2021-09-30 (Crawled : 19:00) - biospace.com/
ABBV | News | $166.43 1.08% 2M
|
Health Technology
|
| O: 0.33%
H: 1.12%
C: -1.22%
europe risankizumab
AbbVie Presents New Analyses Evaluating RINVOQ® (upadacitinib) in Atopic Dermatitis Across Patient Characteristics and Body Regions at EADV Virtual Congress
Published: 2021-09-30 (Crawled : 19:00) - biospace.com/
ABBV | News | $166.43 1.08% 2M
|
Health Technology
|
| O: 0.33%
H: 1.12%
C: -1.22%
dermatitis atopic dermatitis
Gainers vs Losers
| 71% | 29% |
Top 10 Gainers
AGBA | News | $1.27 217.5% 120M
|
Finance
EGOX | $0.0503 39.72% 320M
|
RWOD | $10.52 31.56% 5.9M
|
n/a
ZCMD | $1.905 31.38% 30M
|
Commercial Services
NVFY | $2.71 28.44% 31M
|
Consumer Durables
MRDB 4 | $0.536 27.65% 2M
|
n/a
BSFC | $0.0822 27.64% 75M
|
Manufacturing
TPET | $0.4121 25.68% 45M
|
n/a
INDO | $5.1 25.0% 15M
|
Energy Minerals
CHRO | $1.53 24.9% 100K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.